Ischemic cardiomyopathy's prognosis depends on disease state and chronicity. A big component in determining prognosis is myocardial viability. Larger myocardial viability is associated with better outcomes in patients who undergo revascularization as there is a possibility of muscle recovery. Patients with non-viable myocardial injury are recommended pharmaceutical management as outlined above. With proper treatment and lifestyle modifications, the clinical course of IC can be stabilized significantly.